EDX110 to help heal diabetic foot ulcers

A Multi-Centre, Observer-Blinded, Randomized Controlled Trial of EDX110 for the Treatment of Diabetic Foot Ulcers

This trial will test whether adding the EDX110 dressing to standard wound care helps adults with hard-to-heal diabetic foot ulcers heal faster than standard care alone.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 298 (estimated)
• Ages: 18 Years to 90 Years
• Sex: All
• Sponsor: ConvaTec Inc. (Industry-sponsored)
• Drugs / interventions: chemotherapy, radiation
• Locations: 4 sites (Phoenix, Arizona and 3 other locations)
• Trial ID: NCT07209358 on ClinicalTrials.gov

What this trial studies

This is a prospective, multi-center, observer-blinded, pre-market 1:1 randomized controlled trial comparing the addition of the EDX110 dressing system plus standard of care versus standard of care alone for diabetic foot ulcers. Adults enrolled must have a non-healing full-thickness (Wagner grade 1) ulcer located distal to the malleolus that has failed to progress for at least four weeks. Participants are randomized at three U.S. clinical sites and undergo periodic wound assessments by blinded observers to measure healing outcomes over a defined follow-up period. Patients with only mild superficial infection (PEDIS grade 1) may be included, while deeper or more severe infections are excluded.

Who should consider this trial

Good fit: Adults aged 18 or older with a non-healing full-thickness (Wagner grade 1) diabetic foot ulcer located on the foot distal to the malleolus that has not progressed for at least four weeks, including those with only mild superficial infection (PEDIS grade 1).

Not a fit: Patients with deeper or more severe ulcers (Wagner grade >1), ulcers proximal to the malleolus, moderate or severe infection (PEDIS >1), or those unable to attend study visits are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, adding EDX110 could increase healing rates or speed healing of diabetic foot ulcers, potentially reducing complications like infection and amputation.

How similar studies have performed: Advanced dressing systems and adjunctive wound therapies have shown benefit in some prior trials, but the EDX110 system itself is pre‑market and has not yet been widely proven in randomized studies.

Eligibility criteria

Inclusion Criteria:

* Participants at least 18 years old and willing to participate in all procedures and follow-up evaluations necessary to complete the study.
* The participant must have an index ulcer meeting the following characteristics:

  1. Non-healing DFU defined as; at least 4 weeks prior to enrolment the ulcer has failed to progress on a healing trajectory.
  2. Full-thickness wound; defined as Wagner Diabetic Foot Ulcer Grade 1 - superficial ulcer of skin or subcutaneous tissue.
  3. Located on the anatomical foot; defined as distal to the medial or lateral malleolus.
* Presents with or without clinical signs of superficial infection. Infection is defined using International Working Group of the Diabetic Foot (IWGDF) PEDIS classification and for the purpose of inclusion infections must be PEDIS grade 1 (Mild); Infected: At least two of these items are present: Local swelling or induration Erythema \>0.5 but \<2 cm2 around the wound, Local tenderness or pain, Local increased warmth, Purulent discharge.
* Ulcer duration at randomization must be present for ≥1 month but less than \<24 months in duration.
* Post-debridement wound area is ≥0.1 cm2 and ≤25 cm2.
* If two or more ulcers either mono or bilateral are present, the index ulcer must additionally be:

  1. The ulcer with the largest wound area, as long as it meets all other criteria.
  2. ≥3cm distance from any other ulcer on the affected limb
* Known history of type 1 or type 2 diabetes (confirmed by the subject's medical history).
* HgbA1c \<12% (NGSP) OR 108 mmol/mol (IFCC) OR average blood glucose 298 mg/DL.
* Participant has adequate circulation to the affected extremity as defined by Wound, Ischemia, foot Infection (WIfI) Ischemia grades 0-1 (no PAD to Mild PAD).
* Participants are required to have either.

  1. Ankle-Brachial Index (ABI) by Doppler: ≥0.6 OR Toe-Brachial Index (TBI) ≥ 0.5
  2. OR Dorsum transcutaneous oxygen test (TcPO2): \>40 mm/Hg

Exclusion Criteria:

* Participants with wounds that have any of the following characteristics:

  1. Wagner Grade 2 - ulcers extend into tendon, bone, or capsule
  2. Grade 3 - deep ulcer with osteomyelitis, or abscess
  3. Grade 4 - partial foot gangrene
  4. Grade 5 - whole foot gangrene
* Infections that are classified as:

  1. PEDIS 3 (Moderate): Infection with no systemic manifestations and involving: Erythema extending ≥2 cm2 from the wound margin, and/or tissue deeper than skin and subcutaneous tissues (e.g., tendon, muscle, joint, and bone).
  2. PEDIS 4 (Severe): All of the above in PEDIS 3 plus manifestations (of the systemic inflammatory response syndrome \[SIRS\]).
  3. In addition, any diabetic foot infections with; Confirmed underlying bone involvement (osteomyelitis) based on; imaging (plain X-ray, CT or MRI), clinical examination (exposed bone or positive probe to bone test) or culture/histopathology of a bone specimen
  4. OR Cellulitis/lymphangitis/soft tissue gas or necrotizing fasciitis originating from the wound site.
* Tunnelling, Cavity or undermining wounds.
* Known or suspected local skin malignancy at the site of the ulcer.
* A wound that is actively bleeding. This does not exclude enrollment once active bleeding has stopped (hemostasis).
* Gross Foot deformities that would interfere with proper off-loading or proper wound healing i.e. non-active charcot foot, rocker bottom foot, gross digital deformities.
* Active Charcot deformity.
* Wound duration \>2 years.
* Participants receiving any of the following prior therapies. In the last 30 days:

  1. Has required systemic corticosteroids \>10mg/kg/day OR
  2. Participant has required Chemoradiation (chemotherapy and/or radiation therapy) to treat cancer and is immunocompromised OR
  3. Participant is anticipated to require such medications during the study period.
  4. Study ulcer treatment with any advanced therapy, including, biomedical or topical growth factors, tissue engineered materials (e.g., Apligraf or Dermagraft), sterilized placental allografts (EpiFix, NovaFix, etc.), or other scaffold materials (e.g., OASIS® Wound Matrix, MatriStem Wound Matrix).
  5. Has undergone any amputation to the affected leg.
* Known hypersensitivity to constituents of the product.
* Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of, or compliance with the study protocol in the judgement of the Investigator.
* Women of childbearing age (women aged \<55 years who have not undergone menopause) who are:

  1. Pregnant at time of enrolment
  2. Breast-feeding
* Concurrent enrolment in any other study.

Where this trial is running

Phoenix, Arizona and 3 other locations

• Axentra Bio — Phoenix, Arizona, United States (Recruiting)
• Clemente Clinical Research — Santa Ana, California, United States (Recruiting)
• ILD Research Center — Vista, California, United States (Recruiting)
• Futuro Clinical Trials — McAllen, Texas, United States (Recruiting)

Study contacts

• Study coordinator: Andrea M Picchietti

Conditions Wound Heal; Diabetic Foot Ulcer; Hard to heal wounds